MedTrace Logo

Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation

NCT07642908 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2026-06-11

No results posted yet for this study

Summary

This study explores how a specific genetic mutation of leucine-rich repeat kinase 2 (LRRK2) affects individuals with Parkinson's disease (PD), comparing those with the mutation to others with Parkinson's disease and without the mutation (iPD). Participants will complete positron emission tomography (PET) and magnetic resonance imaging (MRI) brain imaging, cognitive tests, motor tests, sensory tests, and questionnaires. The aims of this study are to compare brain chemicals in LRRK2 PD patients with iPD patients and to correlate brain chemicals with motor and cognitive tests in LRRK2 PD and iPD patients.

Conditions

  • Parkinson Disease

Sponsors & Collaborators

Principal Investigators

  • Prabesh Kanel, PhD · University of Michigan

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-18
Primary Completion
2026-09-17
Completion
2026-09-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07642908 on ClinicalTrials.gov